CD82, also known as metastasis suppressor Kangai-1 (KAI1). Recent studies have shown its function as a metastasis suppressor in various tumors. In addition, it may also serve as a marker for activation/differentiation of mononuclear cells. In normal tissue, CD82 labels activated/differentiated hematopoietic cells and some glandular epithelial cells. In tumors, the expression of CD82 has been shown to be downregulated in tumor progression. CD82 can be activated by p53 through a consensus binding sequence in the promoter. Loss of p53 function, which is commonly observed in many types of cancers, may lead to the downregulation of the CD82 gene. The correlation between lower or no expression of CD82 and poor tumor prognosis is observed in many types of tumors, including prostate, breast, colon, stomach, bladder, lung, liver, pancreas, and ovary tumors.
CD82, also known as metastasis suppressor Kangai-1 (KAI1). Recent studies have shown its function as a metastasis suppressor in various tumors. In addition, it may also serve as a marker for activation/differentiation of mononuclear cells. In normal tissue, CD82 labels activated/differentiated hematopoietic cells and some glandular epithelial cells. In tumors, the expression of CD82 has been shown to be downregulated in tumor progression. CD82 can be activated by p53 through a consensus binding sequence in the promoter. Loss of p53 function, which is commonly observed in many types of cancers, may lead to the downregulation of the CD82 gene. The correlation between lower or no expression of CD82 and poor tumor prognosis is observed in many types of tumors, including prostate, breast, colon, stomach, bladder, lung, liver, pancreas, and ovary tumors.
CD82, also known as metastasis suppressor Kangai-1 (KAI1). Recent studies have shown its function as a metastasis suppressor in various tumors. In addition, it may also serve as a marker for activation/differentiation of mononuclear cells. In normal tissue, CD82 labels activated/differentiated hematopoietic cells and some glandular epithelial cells. In tumors, the expression of CD82 has been shown to be downregulated in tumor progression. CD82 can be activated by p53 through a consensus binding sequence in the promoter. Loss of p53 function, which is commonly observed in many types of cancers, may lead to the downregulation of the CD82 gene. The correlation between lower or no expression of CD82 and poor tumor prognosis is observed in many types of tumors, including prostate, breast, colon, stomach, bladder, lung, liver, pancreas, and ovary tumors.
